Development Portfolio by Therapeutic Area

Listed below are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 2, 2023. Whether any of the listed compounds ultimately becomes a marketed product depends on the results of clinical studies, the competitive landscape of the potential product's market, reimbursement decisions by payers and the manufacturing processes necessary to produce the potential product on a commercial scale, among other factors. There can be no assurance that we will seek regulatory approval of any of these compounds or that, if such approval is sought, it will be obtained. There is also no assurance that a compound which gets approved will be commercially successful. At this stage of development, we cannot determine all intellectual property issues or all the patent protection that may, or may not, be available for these investigational compounds.

Hematology

Phase I

Additional Indications

OPDIVO
– Hematologic Malignancies

Investigational Compounds

alnuctamab BCMA TCE
– Relapsed/Refractory Multiple Myeloma

Anti-SIRPα
– Hematologic Malignancies

BCMA ADC^
– Relapsed/Refractory Multiple Myeloma

BCMA NKE
– Relapsed/Refractory Multiple Myeloma

BET Inhibitor (CC-90010)^
– Hematologic Malignancies

CD33 NKE
– Relapsed/Refractory Multiple Myeloma

CD47xCD20
– Non-Hodgkin's Lymphoma

CK1α Degrader
– Hematologic Malignancies

GPRC5D CAR-T
– Relapsed/Refractory Multiple Myeloma

GSPT1 CELMoD (CC-90009)^
– Relapsed/Refractory Acute Myeloid Leukemia

iberdomide^
– 1L Diffuse Large B-cell Lymphoma
– 3L+ Follicular Lymphoma
– Relapsed/Refractory Non-Hodgkin Lymphoma
– Large B-cell Lymphoma

Phase II

Additional Indications

ABECMA[a]
– 1-4L+ Multiple Myeloma

BREYANZI
– 3L+ Chronic Lymphocytic Leukemia
– 3L+ Follicular Lymphoma
– 3L+ Marginal Zone Lymphoma
– 3L+ Mantle Cell Lymphoma

ONUREG
– Low-to-Intermediate risk MDS

OPDIVO[a] ***+ EMPLICITI***[a]
– Relapsed/Refractory Multiple Myeloma

REBLOZYL[a]
– A-Thalassemia SubQ

IDHIFA
– 1L Acute Myeloid Leukemia

Investigational Compounds

A/I CELMoD (CC-99282)^
– Relapsed/Refractory Non-Hodgkin Lymphoma

BET Inhibitor (BMS-986158)
– Hematologic Malignancies

iberdomide
– Newly-Diagnosed Multiple Myeloma

Phase III

Additional Indications

ABECMA[a]
– 3-5L Multiple Myeloma

INREBIC
– MF Previously treated with Ruxolitinib

REBLOZYL[a]
– 1L TD MDS Associated Anemia
– 1L TD MF Associated Anemia

Investigational Compounds

iberdomide
– 2L+ Multiple Myeloma

mezigdomide (CC-92480)
– 2L+ Multiple Myeloma

Approved Indications

ABECMA
– 5L+ Relapsed/Refractory Multiple Myeloma
– 4L+ Relapsed/Refractory Multiple Myeloma

BREYANZI
– 2L Large B-cell Lymphoma
– 3L+ Large B-cell Lymphoma

EMPLICITI[a] ***+ POMALYST/IMNOVID***
– Relapsed/Refractory Multiple Myeloma

EMPLICITI[a] ***+ REVLIMID***
– Relapsed/Refractory Multiple Myeloma

IDHIFA
– Relapsed/Refractory Acute Myeloid Leukemia

INREBIC
– Myelofibrosis

ONUREG
– Post-Induction Acute Myeloid Leukemia Maintenance

OPDIVO[a]
– Advanced Hodgkin Lymphoma

POMALYST/IMNOVID
– Multiple Myeloma
– Relapsed/Refractory Multiple Myeloma
– AIDS related Kaposi Sarcoma
– HIV-negative Kaposi Sarcoma

REBLOZYL[a]
– Transfusion-Dependent Beta-Thalassemia
– MDS Previously treated with ESA

REVLIMID
– 1L Multiple Myeloma
– Mantle Cell Lymphoma
– MDS
– Multiple Myeloma
– Previously treated Follicular Lymphoma
– Relapsed/Refractory Adult T-cell Leukemia/Lymphoma

SPRYCEL
– 1L CML
– Pediatric ALL
– Refractory CML

Development Portfolio by Therapeutic Area

Oncology

Phase I

Additional Indications

OPDIVO*

– Solid Tumors

OPDIVO* **+ *YERVOY****

– Solid Tumors

Investigational Compounds

AHR Antagonist^

– Solid Tumors

Anti-CCR8^

– Solid Tumors

Anti-ILT4^*

– Solid Tumors

AR-LDD^

– Solid Tumors

Anti-NKG2A^

– Solid Tumors

Claudin 18.2 ADC*

– Advance Solid Tumors

CD3xPSCA Bispecific

– Solid Tumors

DGK Inhibitor

– Solid Tumors

JNK Inhibitor

– Solid Tumors

LSD1 Inhibitor^

– Solid Tumors

MAGE A4/8 TCER*

– Solid Tumors

SHP2 Inhibitor*^

– Solid Tumors

TGFβ Inhibitor^

– Solid Tumors

TIGIT Bispecific*

– Solid Tumors

Phase II

Additional Indications

OPDIVO*

– Solid Tumors

– 2L CRC

– Pan Tumor TMB High

OPDIVO* **+ *YERVOY****

– Solid Tumors

– 2L Metastatic Castration-Resistant Prostate Cancer

OPDIVO* **+ *CDK4/6 Inhibitor***

– Neoadjuvant ER+/HER2- Breast

nivolumab + relatlimab

– 1L Stage IV NSCLC

– 1L/2L Hepatocellular carcinoma

Investigational Compounds

Anti-CTLA-4 NF Probody Therapeutic

– Solid Tumors

Anti-Fucosyl GM1^

– Solid Tumors

Anti-IL8^

– Solid Tumors

Anti-TIGIT^

– Solid Tumors

BET Inhibitor (CC-90010)^

– Solid Tumors

farletuzumab-ecteribulin*

– Solid Tumors

repotrectinib

– ROS1 NSCLC

– NTRK Pan Tumor

Phase III

Additional Indications

OPDIVO*

– Peri-adjuvant Muscle Invasive Urothelial Carcinoma

– Adjuvant Gastric Cancer

– Adjuvant HCC

– Adjuvant Melanoma

– 1L Metastatic Castration-Resistant Prostate Cancer

– Peri-adjuvant NSCLC Stage IB-IIIA Adjuvant NSCLC#

OPDIVO* **+ *YERVOY****

– 1L Bladder Cancer

– 1L HCC

– 1L+ MSI-High CRC h

– Adjuvant RCC

– Stage III Unresectable NSCLC

OPDUALAG (fixed dose nivolumab + relatlimab)*

– Adjuvant Melanoma

– 2L+ Microsatellite Stable Metastatic CRC

– 1L Melanoma SubQ

Investigational Compounds

subcutaneous nivolumab + rHuPH20*

– 2L RCC

– Adjuvant Melanoma

Approved Indications

ABRAXANE

– Breast

– Gastric

– Locally Advanced or Metastatic NSCLC

– Metastatic Breast Cancer

– NSCLC

– Pancreatic

– Unresectable Pancreatic

OPDIVO*

– 1L Metastatic Melanoma

– 1L Gastric

– Esophageal Squamous Cell Carcinoma

– 1L Esophageal

– Adjuvant Melanoma

– Adjuvant Bladder

– Adjuvant Esophageal/ Gastroesophageal

– Mesothelioma

– Previously treated advanced RCC

– Previously treated Gastric cancer (Japan, China)

– Previously treated Metastatic Head & Neck

– Previously treated Metastatic Melanoma

– Previously treated Metastatic MSI-High CRC

– Previously treated Metastatic Non-squamous NSCLC

– Previously treated Metastatic Squamous NSCLC

– Previously treated Metastatic Urothelial Cancer

– Previously treated Esophageal Cancer

– Neoadjuvant NSCLC

OPDIVO* **+ cabozantinib***

– Metastatic RCC

OPDIVO* **+ *YERVOY****

– 1L Metastatic Melanoma

– 1L Mesothelioma

– 1L NSCLC

– 1L RCC

– Previously treated Metastatic MSI-High CRC

– Previously treated HCC

– 1L Esophageal

– 1L Gastric

OPDUALAG **(fixed dose nivolumab + relatlimab)**

– 1L Melanoma

YERVOY*

– Adjuvant Melanoma

– Metastatic Melanoma

Development Portfolio by Therapeutic Area

Immunology

Phase I

Investigational Compounds

afimetoran (TLR7/8 Inhibitor)
– Cutaneous Lupus Erythematosus

Anti-CD40
– Autoimmune Disease

RIPK1 Inhibitor
– Autoimmune Disease

IL2-CD25
– Autoimmune Disease

PKCθ Inhibitor
– Autoimmune Disease

TYK2 Inhibitor
– Autoimmune Disease

Phase II

Additional Indications

***SOTYKTU* (deucravacitinib)**
– Crohn's Disease
– Alopecia Areata
– Ulcerative Colitis
– Discoid Lupus Erythematosus

Investigational Compounds

Afimetoran
– Systemic Lupus Erythematosus

Phase III

Additional Indications

***SOTYKTU* (deucravacitinib)**
– Psoriatic Arthritis
– Systemic Lupus Erythematosus

ZEPOSIA
– Crohn's Disease

Investigational Compounds

cendakimab
– Eosinophilic Esophagitis

Approved Indications

ORENCIA
– Active Polyarticular JIA
– Early Rheumatoid Arthritis
– JIA Intravenous
– JIA Subcutaneous
– Psoriatic Arthritis
– RA Auto injector
– RA Intravenous
– RA Subcutaneous
– Acute Graft versus Host Disease

***SOTYKTU* (deucravacitinib)**
– Moderate-to-Severe Psoriasis

ZEPOSIA
– Relapsing Multiple Sclerosis
– Moderate-to-Severe Ulcerative Colitis

Cardiovascular

Phase I

Investigational Compounds

Factor XIa Inhibitor[^]
– Thrombotic Disorders

Phase II

Additional Indications

***CAMZYOS* (mavacamten)**
– Heart Failure with Preserved Ejection Fraction (HFpEF)

Investigational Compounds

Cardiac Myosin Inhibitor (MYK-224)
– Obstructive Hypertrophic Cardiomyopathy

danicamtiv
– Genetic Dilated Cardiomyopathy

Phase III

Additional Indications

***CAMZYOS* (mavacamten)**
– Non-obstructive Hypertrophic Cardiomyopathy

Investigational Compounds

milvexian[^]
– Secondary Stroke Prevention (SSP)[#]

Approved Indications

***CAMZYOS* (mavacamten)**
– Symptomatic Obstructive Hypertrophic Cardiomyopathy

ELIQUIS[^]
– Stroke Prevention in Atrial Fibrillation
– Venous Thromboembolism Prevention
– Orthopedic Surgery
– Venous Thromboembolism Treatment

Fibrotic Diseases

Phase II

Investigational Compounds

HSP47[^]
– Non-Alcoholic Steatohepatitis

LPA_1 Antagonist
– Pulmonary Fibrosis

Neuroscience

Phase I

Investigational Compounds

Anti-Tau[^]
– Neuroscience

BTK Inhibitor
– Neuroscience

eIF2b Activator[^]
– Neuroscience

FAAH/MGLL Dual Inhibitor
– Neuroscience

Note: Above pipeline excludes clinical collaborations

[^] Development Partnerships: ***ABECMA* (ide-cel)**: 2seventy bio; **AHR**: Ikena Oncology; **Anti-Tau**: Prothena; ***CAMZYOS*** in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio; **Claudin 18.2 ADC**: LaNova Medicines; **CD3xPSCA**: Avencell; **eIF2b Activator**: Evotec; ***ELIQUIS***: Pfizer; ***EMPLICITI***: AbbVie; **farletuzumab ecteribulin**: Eisai; **HSP47**: Nitto Denko Corporation; **rHuPH20**: Halozyme; **IDHIFA**: Servier; **MAGEA4/8 TCER**: Immatics; **milvexian**: Janssen Pharmaceuticals, Inc.; ***OPDIVO***, ***YERVOY***, ***OPDUALAG***: Ono; ***REBLOZYL***: Merck; **SHP2 Inhibitor**: BridgeBio Pharma; **TIGIT Bispecific**: Agenus; **PKCθ Inhibitor**: Exscientia

^ Trial(s) exploring various combinations

Partner-run study